Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

作者
Fahua Deng,Weijie Ma,Sixi Wei
出处
期刊:Cancers [Multidisciplinary Digital Publishing Institute]
卷期号:18 (2): 207-207 被引量:8
标识
DOI:10.3390/cancers18020207
摘要

The mesenchymal–epithelial transition (MET) receptor is a tyrosine kinase activated by its sole known ligand, hepatocyte growth factor (HGF). MET signaling regulates key cellular processes, including proliferation, survival, migration, motility, and angiogenesis. Dysregulation and hyperactivation of this pathway are implicated in multiple malignancies, including lung, breast, colorectal, and gastrointestinal cancers. In non–small cell lung cancer (NSCLC), aberrant activation of the MET proto-oncogene contributes to 1% of known oncogenic drivers and is associated with poor clinical outcomes. Several mechanisms can induce MET hyperactivation, including MET gene amplification, transcriptional upregulation of MET or HGF, MET fusion genes, and MET exon 14 skipping mutations. Furthermore, MET pathway activation represents a frequent mechanism of acquired resistance to EGFR- and ALK-targeted tyrosine kinase inhibitors (TKIs) in EGFR- and ALK-driven NSCLCs. Although MET has long been recognized as a promising therapeutic target in NSCLC, the clinical efficacy of MET-targeted therapies has historically lagged behind that of EGFR and ALK inhibitors. Encouragingly, several MET TKIs such as capmatinib, tepotinib, and savolitinib have been approved for the treatment of MET exon 14 skipping mutations. They have also demonstrated potential in overcoming MET-driven resistance to EGFR TKIs or ALK TKIs. On 14 May 2025, the U.S. Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv for adult patients with locally advanced or metastatic non-squamous NSCLC whose tumors exhibit high c-Met protein overexpression and who have already received prior systemic therapy. In this review, we summarize the structure and physiological role of the MET receptor, the molecular mechanisms underlying aberrant MET activation, its contribution to acquired resistance against targeted therapies, and emerging strategies for effectively targeting MET alterations in NSCLC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Alice3088发布了新的文献求助10
1秒前
希望天下0贩的0的应助被Dante采纳,获得10
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
雪山大地发布了新的文献求助10
2秒前
WXH完成签到,获得积分10
2秒前
丘比特的应助被李玲玲采纳,获得10
2秒前
不安的硬币完成签到,获得积分10
2秒前
RAN发布了新的文献求助10
2秒前
DW的应助被当你采纳,获得10
3秒前
李zihua发布了新的文献求助10
3秒前
4秒前
十八发布了新的文献求助10
4秒前
sciexplorer完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
yyyyy发布了新的文献求助10
5秒前
李健的应助被LL采纳,获得10
5秒前
烟花的应助被xu采纳,获得10
6秒前
甜美紫真发布了新的文献求助10
6秒前
YM完成签到,获得积分10
6秒前
小秀发布了新的文献求助10
6秒前
7秒前
WWWW发布了新的文献求助10
7秒前
samo发布了新的文献求助10
8秒前
CodeCraft的应助被神勇的煎蛋采纳,获得10
8秒前
fantasy的应助被SKHC采纳,获得10
9秒前
自觉的以菱完成签到,获得积分10
9秒前
科研通AI6.4的应助被qqe采纳,获得10
9秒前
阿爸嘚嘚嘚完成签到,获得积分10
11秒前
852的应助被大睡神采纳,获得10
11秒前
12秒前
姚美阁完成签到 ,获得积分10
12秒前
13秒前
鱼鱼鱼鱼发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982